Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such inves
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
SAN DIEGO, April 16, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
09:00am, Thursday, 16'th Apr 2026
LOS ANGELES, April 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against ImmunityBio, Inc.
IBRX INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc.
08:38am, Thursday, 16'th Apr 2026
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
SAN DIEGO, April 15, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026
08:00pm, Wednesday, 15'th Apr 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investors of the May 26, 2026 deadline to seek the rol
IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm
05:59pm, Wednesday, 15'th Apr 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 202 6? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman
02:59pm, Wednesday, 15'th Apr 2026
SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBi
LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 26, 2026 deadline to file a lead plaintiff motion in the class action filed on b
New York, New York--(Newsfile Corp. - April 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Wednesday, 15'th Apr 2026
New class action for ImmunityBio, Inc. (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/26
IBRX EQUITY ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
10:27am, Wednesday, 15'th Apr 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights
09:36am, Wednesday, 15'th Apr 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - April 15, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio
